Navigation Links
FDA: Orphan Drug Workshops Scheduled For Feb. 25-26 and Aug. 3-4, 2010
Date:12/23/2009

Agency Experts to Provide Guidance on Applying for Orphan Drug Designation

SILVER SPRING, Md., Dec. 23 /PRNewswire-USNewswire/ -- As part of its continuing effort to make the agency more transparent and accessible, the FDA has scheduled a series of workshops about orphan drug designation for academics, biotechnology companies, and those unfamiliar with the process. The FDA can grant a special status, known as orphan designation, for drug products intended to treat rare diseases.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Orphan drugs are either drug or biologic products used to treat conditions affecting fewer than 200,000 people in the United States. Orphan drugs may be already-approved or experimental drugs.

The workshops will be held Feb. 25-26, 2010, in Claremont, Calif., and Aug. 3-4, 2010, in Minneapolis. At the workshops, participants will propose a specific drug for a specific rare disease and work on an orphan designation application to submit to the FDA at the conclusion of the workshop. To help participants develop strong applications, FDA staff will provide one-on-one regulatory help.

To obtain orphan drug designation, drugs must be for the treatment, prevention or diagnosis of a rare disease or condition. Designation also requires there be a medical rationale for expecting the proposed drug to be effective in the treatment, prevention, or diagnosis of that disease or condition.

Orphan designation qualifies the applicant to receive certain benefits, such as tax credits and marketing incentives, from the federal government in exchange for developing the drug. After designation, the drug mus
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
2. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
3. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
4. Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
5. Voices to Unite in Los Angeles for 6,000 Children Orphaned Daily
6. Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
7. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
8. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
9. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
10. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
11. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Pharmacyclics, Inc. (the "Company") (Nasdaq: ... Journal of Medicine ( NEJM ) published results ... Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib in patients with ... ibrutinib may be effective and generally well-tolerated in patients ... separate study examining the safety and efficacy of ibrutinib ...
(Date:6/19/2013)... BRAINTREE, Mass. , June 19, 2013 /PRNewswire/ ... announced several important developments in the pursuit of ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) , ... SANM ) for the future production of medical ... , Massachusetts. Sanmina is a leading global provider of ...
(Date:6/19/2013)... 2013 /PRNewswire-iReach/ -- Robert M. Bernstein, M.D., ... procedures and founder of Bernstein Medical – Center ... Doctors, issue of New York Magazine for the ... ) Dr. Bernstein earned his ... reputation as world-renowned hair restoration physician, through a ...
Breaking Medicine Technology:Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 2Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 4Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 5Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 6Haemonetics Announces Next Steps in Manufacturing Transformation 2Haemonetics Announces Next Steps in Manufacturing Transformation 3Haemonetics Announces Next Steps in Manufacturing Transformation 4Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 2Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 3
... 27 Kinex Pharmaceuticals will present results from a Phase ... Meeting in Orlando, on May 29, 2009. The study ... (RPCI) and Fox Chase Cancer Center. Dr. Alex Adjei, ... "Results of a phase I trial of KX2-391, a novel ...
... Administered in Dual Cord Blood Transplant for Hematologic MalignancyLA JOLLA, ... announced today that the first patient has been treated ... molecule Stem Cell Modulator (SCM) designed to increase hematopoietic stem ... pathways that guide cell fate. The study, which is ...
Cached Medicine Technology:Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 2Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 3Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 4
(Date:6/19/2013)... CCA , America's leader in partnership ... Vice President, Health Services, effective June 8, 2013. ... for CCA. He will replace the retiring Herb ... to lead CCA's dedicated team of health care professionals. ... and our partners as we provide effective care to ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Strict ... In July 2013, Orriant is launching a new ... and maintain compliance with regulations. New HHS ... receive wellness incentives if their employer offers outcome-based, ... have been compliant with these standards for nearly ...
(Date:6/19/2013)... Citi Bike has come to New York City ... Perna to know for sure how many patients will choose to ... have the option. In fact, he’s happy about anything that ... make it more convenient for them to visit his office at ... Complimentary Alternative Medicine at Back and Body Medical and an experienced ...
(Date:6/19/2013)... surgery have had a significant impact on survival ... injuries, including burns. Patients who survive the ... greatest risk from infections particularly the overwhelming, ... from inflammation-induced multiorgan failure. Now, a device ... measures the movement of key immune cells may ...
(Date:6/19/2013)... (June 19, 2013) The results of three important ... Neurosurgery , official journal of the Congress ... by Lippincott Williams & Wilkins , a part ... indicates that continuous "machine learning" using artificial neural networks ... patients with advanced brain cancers. Another study in the ...
Breaking Medicine News(10 mins):Health News:CCA Names Dr. John Baxter Vice President, Health Services 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 3Health News:Restoring appropriate movement to immune cells may save seriously burned patients 2Health News:Restoring appropriate movement to immune cells may save seriously burned patients 3Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3
... leukemia, also shows promise against a type of stomach cancer ... a promising anti-leukemia drug for treatment of a relatively rare ... pill once a day, is effective in treating both forms ... cancer cells without attacking healthy cells and causing severe side ...
... mothers can modify the length of other women's menstrual ... mother - or their infants - made the cycles ... Ohio University.// ,She suggests this is due to ... as part of a human's desire to raise children ...
... Hopkins University School of Medicine have recently found that the ... that lets us stop smelling something, even though the odour ... issue of the journal Science show that a protein called ... job of these reurons is to detect smells and send ...
... immune cells which help protect us from disease does not ... it could be something to do with their shape. ... how immune cells behave in microgravity as part of their ... ,It has been found that astronauts have elevated virus levels ...
... The Federal Drug Administration approved OxyContin in late 1995 ... early 1996. Between that time and 2000, prescriptions for ... that they could get a powerful heroin-like high by ... powder.// ,Abuse of OxyContin, the nation's best ...
... Kava is derived from a leafy plant native to the ... implicated in approximately 25 cases of liver diseases. The herb ... to treat insomnia, anxiety, stress and muscle spasms. According to ... as// benzodiazepines but is not chemically related. ,Benzodiazepines have ...
Cached Medicine News:Health News:Immune cells halt round in space 2
Intended for the quantitative determination of magnesium in serum or plasma. Reaction: Endpoint. Wavelength: 520 nm. Linearity: 6.0 mg/dL (2.5 mmol/L)....
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution....
For the quantitative determination of total glucose in serum....
Glucose reagent is used for the quantitative determination of glucose in human serum....
Medicine Products: